Recent Press Releases

Celgene Acquires Late-Stage Product for Crohn's Disease and Other Gastrointestinal Disorders

- GED-0301 is a First-in-Class, Oral Antisense Drug Targeting Smad7 mRNA - Phase III Program for Crohn's Disease Targeted to Begin by Year-End 2014 April 24, 2014 07:30 AM Eastern Daylight Time...

Hyperion Therapeutics to Broaden Orphan Disease Pipeline With Acquisition of Andromeda Biotech Ltd.

Apr 24, 2014 (GLOBE NEWSWIRE via COMTEX) -- --DiaPep277®, a First-in-Class Immune Intervention Therapy in Phase 3 Testing for New Onset Type 1 Diabetes-- --Hyperion to Host Analyst/Investor...

Medivation Enters Into License Agreement With OncoFusion for Compounds Targeting Bromodomain Proteins

SAN FRANCISCO, CA and ANN ARBOR, MI--Medivation, Inc. (NASDAQ: MDVN) and OncoFusion Therapeutics, Inc. today announced that they have entered into a research and license agreement for certain...

Hydra Biosciences and Boehringer Ingelheim Announce Worldwide Collaboration to Develop Small-Molecule Inhibitors for the Treatment of Central Nervous System Diseases and Disorders

CAMBRIDGE, Mass. & INGELHEIM, Germany–(BUSINESS WIRE)–April 24, 2014– Hydra Biosciences, Inc., a leader in the field of Transient Receptor Potential (TRP) channel modulation,...

JUNO COMPLETES $176M SERIES A ROUND

SEATTLE (April 24, 2014) – Juno Therapeutics, a biotechnology company focused on bringing forward novel immunotherapies for cancer, today announced the close of its Series A round with $176M in...

BioTime to Present at GTC Stem Cell Summit 2014

BioTime to Present at GTC Stem Cell Summit 2014

<0> BioTime, Inc.Judith Segall, 510-521-3390, ext 301 </0>

Hyperion Therapeutics to Broaden Orphan Disease Pipeline With Acquisition of Andromeda Biotech Ltd.

--DiaPep277(R), a First-in-Class Immune Intervention Therapy in Phase 3 Testing for New Onset Type 1 Diabetes-- --Hyperion to Host Analyst/Investor Teleconference Today at 8:45 a.m. EDT (5:45 a.m....

SYLVANT™ (siltuximab) Receives FDA Approval to Treat Multicentric Castleman's Disease (MCD)

SYLVANT™ (siltuximab) Receives FDA Approval to Treat Multicentric Castleman's Disease (MCD) First treatment approved for patients with rare blood disorder HORSHAM, Pa., April 23, 2014...

FDA approves Sylvant for rare Castleman's disease

FDA NEWS RELEASE: FDA approves Sylvant for rare Castleman's disease For Immediate Release: April 23, 2014 The U.S. Food and Drug Administration today approved Sylvant (siltuximab) to treat...

Celgene Acquires Late-Stage Product for Crohn's Disease and Other Gastrointestinal Disorders

- GED-0301 is a First-in-Class, Oral Antisense Drug Targeting Smad7 mRNA - Phase III Program for Crohn's Disease Targeted to Begin by Year-End 2014 SUMMIT, N.J.--Celgene Corporation (NASDAQ:CELG)...

CRISPR Therapeutics Raises $25 Million in Series A Financing and Announces Founding Team of World-Renowned Academics and Clinicians

CRISPR Therapeutics Raises $25 Million in Series A Financing and Announces Founding Team of World-Renowned Academics and Clinicians Media contact pete.chan@tudor-reilly.com CRISPR Therapeutics, a...

Sarepta Therapeutics Announces Proposed Public Offering of Common Stock

Sarepta Therapeutics, Inc. (Nasdaq: SRPT), a developer of innovative RNA-based therapeutics, today announced that it is offering to sell, subject to market and other conditions, up to $100 million of...

Aerpio Therapeutics Closes $22M Financing

CINCINNATI, Apr 23, 2014 (BUSINESS WIRE) -- Aerpio Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases, today announced...

Captisol-Enabled™ (Propylene Glycol-Free) Melphalan Meets Primary Endpoint

CE Melphalan is being developed as a novel version of the well-established conditioning treatment in autologous transplant for patients with multiple myeloma. CE Melphalan does not contain propylene...

Kala Pharmaceuticals Announces $22.5 Million Series B Financing

Ysios Capital Joins as Lead Investor; Proceeds to Advance Four U.S. Clinical Trials for Lead Ophthalmic Product Candidates Waltham, Mass., April 23, 2014Kala Pharmaceuticals, Inc., a leading...

Allergan Adopts One-Year Stockholder Rights Plan

Allergan Adopts One-Year Stockholder Rights Plan IRVINE, Calif.--(BUSINESS WIRE)-- Allergan, Inc. (NYSE: AGN) ("Allergan" or the "Company") today announced that its Board of...

Amgen's First Quarter 2014 Revenues Increased 7 Percent To $4.5 Billion

2014 Revenue and Adjusted EPS Guidance Reaffirmed

THOUSAND OAKS, Calif., April 22, 2014 /PRNewswire/

Epizyme Achieves Lead Candidate Milestone for Third Target in GSK Collaboration, Receives $4 Million in Milestone and License Payments

- Potential Therapeutic Candidates Now Identified for All Three GSK Collaboration Targets - CAMBRIDGE, Mass., April 22, 2014 /PRNewswire/ -- Epizyme, Inc. EPZM +15.39% , a clinical stage...